NCT | Phase | Intervention | Target population | Location | Sample size | Key outcomes |
---|---|---|---|---|---|---|
NCT02766699 | Phase I | Nanoparticles containing doxorubicin tied to bispecific antibodies (EGFR(V)-EDV-Dox) that are specific to the tumor cells of the patients | Recurrent glioblastoma | USA | 20 | Safety, MRI evaluation, recommended phase 2 dose, OS |
NCT03491683 | Phase I/II | INO-9012 (DNA plasmid for IL-12), INO-5401 (WT1 antigen, PSMA, hTERT genes) delivered via electroporation of cells, in combination with cemiplimab, with RT/TMZ | Newly diagnosed glioblastoma | USA | 52 | Adverse events, OS, change in T cell phenotypes |
NCT03750071 | Phase I/II | VXM01 (DNA plasmid vaccine for VEGFR-2) and avelumab (anti-PD-L1) | Recurrent glioblastoma | Germany | 30 | Adverse events, PFS, OS, MRI response, duration of response |
NCT04485949 | Phase IIb | IGV-001 (IGF-1R antisense oligonucleotide with autologous cell antigens) vs placebo with TMZ/RT | Newly diagnosed glioblastoma | USA | 93 | PFS, OS, MGMT status effect, functional changes, adverse events |
NCT04573140 | Phase I/II | Autologous tumor mRNA and pp65 LAMP mRNA-loaded liposomal vaccine | Newly diagnosed pediatric high-grade glioma and adult glioblastoma | USA | 28 | Production feasibility, safety, MTD |